Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

T Mitsudomi - The Lancet Oncology, 2011 - thelancet.com
Clinical practice in non-small-cell lung cancer (NSCLC) has changed greatly since the
introduction of EGFR tyrosine kinase inhibitors (TKIs). Subsequent discovery of activating …
被引用次数：30 相关文章

[引用][C] Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

T Mitsudomi - The Lancet. Oncology, 2011 - pubmed.ncbi.nlm.nih.gov
Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer? Erlotinib,
gefitinib, or chemotherapy for EGFR mutation-positive lung cancer? Lancet Oncol. 2011 Aug;12(8):710-1 …

[引用][C] Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

T Mitsudomi - The Lancet Oncology, 2011 - infona.pl
Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer? × Close The
Infona portal uses cookies, ie strings of text saved by a browser on the user's device. The …

Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

T Mitsudomi - The Lancet. Oncology, 2011 - europepmc.org
A comment on this article appears in" Pharmacokinetics of gefitinib and erlotinib." Lancet
Oncol. 2011 Nov; 12 (12): 1093. This is a comment on" Erlotinib versus chemotherapy as …

[引用][C] Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

T Mitsudomi - The Lancet Oncology, 2011 - Elsevier